natgillin/translations-raw huggingface dataset:
The monolithic intravaginal ring of claim 1, wherein the polysiloxane elastomer is a dimethylpolysiloxane elastomer, and wherein the ratio of progesterone to elastomer is 1:1 to 1:10, the progesterone is homogeneously dispersed in the elastomer, the ratio of progesterone to hydrocarbon or glycerol esters of a fatty acid is 1:0.1 to 1:100, and wherein the progesterone is released from the monolithic intravaginal ring for up to 18 days after administration to the patient. 
Monolitni intravaginalni prsten u skladu s patentnim zahtjevom 1, naznačen time, da je polisiloksan elastomer dimetilpolisiloksan elastomer, a omjer progesterona i elastomera iznosi 1: 1 do 1: 10, progesteron je homogeno raspršen u elastomeru, omjer progesterona i ugljikovodika ili glicerolnih estera masnih kiselina iznosi 1: 0,1 do 1: 100 i pri čemu se progesteron otpušta iz monolitnog intravaginalnog prstena do 18 dana nakon primjene na pacijentu.
It is not important regarding the protection against contamination whether the interior or inside portions of the groove structures are filled with the filling medium as well or not, as long as all openings or connections to the exterior are closed or blocked by the filling medium during mechanical machining. 
Å to se tiče zaštite od onečišćenja unutrašnjosti ili unutarnjih dijelova brazdastih struktura, sve dok su tijekom mehaničke strojne obrade svi otvori ili spojevi s okolinom zatvoreni ili začepljeni s punilom, nije važno je su li one dobro popunjene s punilo ili nisu.
The method of claim 18, wherein the disease is selected from the group consisting of transplantation rejection, host vs. graft disease, graft vs. host disease, leukemia, lymphoma, hyperproliferative vascular disorders, autoimmune disease, diseases of inflammation, solid tumors, and fungal infections. 
Upotreba prema zahtjevu 17, naznačena time da je bolest izabrana iz grupe koju čine odbacivanje transplantata, bolest host vs. graft, bolest graft vs. host, leukemija, limfom, hiperproliferativne vaskularne bolesti, autoimune bolesti, upalne bolesti, solidni tumori i gljivične infekcije.
Q is optionally substituted aryl or heteroaryl; and is hydrogen, optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, alkoxy, aryloxy, alkenyloxy or alkynyloxy. The process according to claim 7, wherein compounds of Formula XXXV are selected from: 
Q je po izboru supstituirani aril ili heteroaril; i R, je vodik, po izboru supstituirani alkil, alkenil, alkinil, cikloalkil, aril, heterociklil, heteroaril, aralkil, alkoksi, ariloksi, alkeniloksi ili alkiniloksi. 8. Postupak u skladu s patentnim zahtjevom 7, naznačen time, da su spojevi Formule XXXV odabrani među sljedećim spojevima:
Advantages of the invention are summarized as follows: 
Datum objave europske prijave patenta:
an antisense oligomer which consists of a nucleotide sequence having deletion, substitution, insertion and/or addition of 1 to 5 nucleotides in the nucleotide sequence of SEQ ID NO: 1 or 2, and has an activity to cause skipping of the 51st exon in the human dystrophin gene; 
antisensni oligomer koji se sastoji od nukleotidne sekvence koja ima deleciju, supstituciju, inserciju i/ili adiciju od 1 do 5 nukleotida u nukleotidnoj sekvenci SEQ ID NO: 1 ili 2, ima aktivnost izazvati preskakanje 51-vog egzona u humanom distrofinskom genu; i
Process according to Claim 9, wherein the white chocolate is in the form of chocolate chips, chunks or sticks. 
Postupak prema zahljevu 9, naznačen time što je bijela čokolada u obliku ljuspica, komadića ili štapića.
Another alternative route to convert the compound of formula (14), or salt thereof, into the compound of formula (1-a), or salt thereof, is detailed in Scheme 11. 
L6d gdje R1 je vodikova ili dušikova zaštitna skupina, naznačen time, da obuhvaća sljedeće korake: a) dobava spoja u skladu sa sljedećom formulom (14) ili njegove soli: 10
One of them consists of copper, arsenic and ammonium acetate. 
Jedna od njih se sastoji od bakra, arsena i amonij acetata.
In another aspect of the invention, the hydrogen chloride is added as gaseous hydrogen chloride. 
Još poželjnije, klorovodik se dodaje kao plinoviti klorovodik.
A suspension of 2-chloro-5-aminobenzonitrile (0.405 g, 2.66 mmol) in glacial acetic acid (20 ml) is treated with concentrated HCl (5 ml). 
Suspenziju 2-klor-5-aminobenzonitrila (0,405 g, 2,66 mmola) u ledenoj octenoj kiselini (20 ml) se pomiješa s koncentriranom HCI (5 ml).
wherein R is a suitable sulphonate ester; from a (C1-C6)alkyl-4-piperidinecarboxylate compound of the Formula III: which process comprises the steps of: 
Postupak za dobivanje spoja formule IIa: naznačen time da R je pogodan sulfonatni ester; iz(C1-C6)alkil-4-piperidinkarboksilatnog spoja prema formuli III:
A method for manufacturing an insulation block, preferably an insulation plate, which insulation block comprises parallel first and second large planar surfaces and parallel first and second long side edges and parallel first and second short side edges perpendicular to the long side edges, delimiting the surfaces, characterised in that in the method 
HR P20181810 T1 PATENTNI ZAHTJEVI 1. = Postupak za proizvodnju izolacijskog bloka, koji sadrži paralelne prvu i drugu veliku ravnu površinu i paralelne prve i druge duge bočne rubove i paralelne prve i druge kratke bočne rubove okomite na duge bočne rubove, koji omeđuju površine, u navedenom postupku -
A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof having the structure of Formula I: wherein R1 is a substituted or unsubstituted heteroaryl, wherein the heteroaryl is selected from the group consisting of and with the proviso that a carbon atom of the R1 heteroaryl is attached to the carbonyl; 
9 HR P20180196 T1 Farmaceutski pripravak naznačen time da sadrži terapeutski učinkovitu količinu spoja prema zahtjevu 1 ili njegovu farmaceutski prihvatljivu sol koji ima strukturu s Formulom I: pri čemu R' je supstituiran ili nesupstituiran heteroaril, pri čemu je heteroaril odabran iz skupine koju čine
An antibody that is specific against the MHC/peptide complex of MHC with a peptide consisting of SEQ ID No. 9. 
Antitijelo koje je specifično protiv MHC/peptidnog kompleksa MHC-a s peptidom koji se sastoji od SEQ ID br. 1. Komplet koji sadrži:
vildagliptin, or the corresponding amount of any of its salts is present in an amount from 15% to 35% by weight; 
(a) vildagliptin, ili odgovarajuća količina bilo koje od njegovih soli, je prisutan količinom od 15% do 35% mase;
a first encoder to LDPC encode Layer 1 signaling data to generate LDPC parity bits; 
LDPC-kodiranje BCH-kodiranih signalnih podataka L1 zbog stvaranja LDPC paritetnih bitova; i probijanje na stvorenim LDPC paritetnim bitovima.
The pharmaceutical composition of claim 9, further comprising an antidiabetic or anti-obesity agent. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 9, naznačen time što dodatno sadrži antidijabetično ili sredstvo protiv pretilosti.
Consequently, kegs travel long distances in their lifetime and the heavier they are the higher the transportation cost. 
Zbog toga, tijekom njihovog vijeka trajanja bačve putuju na velike udaljenosti, i što su one teže, to su veći i troškovi transporta.
An ODT as claimed in claim 1, which is free of lubricant. 
Tableta za oralno disperziranje sukladno patentnom zahtjevu 1, koja ne sadrži lubrikant.
% (2 grade improvement) 94% (no change) 
94% (bez promjene) 67% (poboljšanje 1. stupnja)
An isolated IL-23p19 antibody, comprising a light chain variable region amino acid sequence encoded by the nucleotide sequence selected from the group consisting of SEQ ID NOS:142-144. 
Izolirano IL-23p19 antitijelo prema patentnom zahtjevu 1, naznačeno time da sadrži varijabilnu regiju lakog lanca aminokiselinske sekvence kodirane od strane nukleotidne sekvence izabrane od grupe koja se sastoji od SEQ ID NOS:142-144.
The communication apparatus according to claim 1, wherein the first frame configuration pattern for the first component carrier is different from the second frame configuration pattern for the second component carrier and includes at least one additional transmission timing of an uplink subframe that is not included in the second frame configuration pattern. 
Uređaj bazna stanica prema zahtjevu 1, naznačen time da prvi obrazac konfiguracije okvira za Primarnu Stanicu i drugi obrazac konfiguracije okvira za Sekundarnu Stanicu dijele barem jedno zajedničko vrijeme prijenosa podokvira uzlazne veze.
• no separate adjuvant and/or immune stimulator is added to the composition. 
* nikakva odvojena pomoćna tvar i/ili imuno stimulator nisu dodani u pripravak.
A nasal spray device as claimed in any preceding claim, wherein a maximum transverse dimension of the transfer channel (13) is from 1.0 to 3.0 mm and/or wherein the transfer channel (13) has a length of 3 to 20 mm. 
Nazalni raspršivač za nos sukladno bilo kojem prethodnom zahtjevu, pri čemu prijenosni kanal (13) ima duljinu od 4 do 15 mm, a još poželjnije od 4 do 10 mm.
second labyrinth portions (9a, 9b, 9c, 9d, 9e, 9f) obtained in shaped bodies (9), said second labyrinth portions (9a, 9b, 9c, 9d, 9e, 9f) having matching profiles configured to be tightly coupled with any first labyrinth portion (6a, 6b, 6c, 6d, 6e, 6f) in order to form more labyrinths once the coupling operation has been completed. 
- < druge labirintne dijelove (9a, 9b, 9c, 9d, Je, 9f) izvedene u oblikovanim tijelima (9), te navedeni drugi labirintni dijelovi (9a, 9b, 9c, 9d, Je, 9f) imaju odgovarajuće profile koji su konstruirani da se čvrsto povezuju s bilo kojim prvim labirintnim dijelom (6a, 6b, 6c, 6d, 6e, 6f) kako bi se nakon što se dovrši operacija spajanja stvorilo još labirinata.
The method of claim 15, wherein said asthma is allergic asthma. 
Spoj za uporabu prema patentnom zahtjevu 26 naznačen time što astma je alergijska astma.
For example, pharmaceutically acceptable salts of compounds described herein are synthesized from the corresponding compound, that contains an acid or basic group, by conventional chemical methods. 
Na primjer, farmaceutski prihvatljive soli ovdje opisanih spojeva sintetizirane su od odgovarajućeg spoja, koji sadrži kiselinsku ili bazičnu skupinu, uobičajenim kemijskim metodama.
The arrester according to claim 1, characterized in that the insulating body has an increased thickness in zones where the discharge chambers open to the surface of the insulating body. 
Gromobran u skladu s patentnim zahtjevom 1, naznačen time što izolirajuće tijelo (1) ima povećanu debljinu u područjima gdje su lučne komore (5) otvorene prema površini izolirajućeg tijela (1).
A slurry bed of solids formed during this age time [the solution can be seeded with 0.5 to 5 wt% of small particle size (alpine milled) monohydrate]. 
Za to vrijeme se formirao talog smjese krutina (u otopinu se može staviti klica kristala od 0.5 do 5 težinski% monohidrata male veličine čestica (struganih)).
5×106 L 1210 cells were injected subcutaneously in the axillary region of DBA/2 mice (groups of 8 mice/treatment). 
5 x 10" stanica L 1210 injektirano je subkutano u aksilarnu regiju DBA/2 miševa (skupine od 8 miševa/tretman).
a light emitting diode disposed on the first end of said conductive housing; and 
- < LED dioda postavljena na jednom kraju provodnog kućišta; i
The solid form of claim 1, which exhibits a weight loss of 5.00% of the total sample weight upon heating from about 30 to about 110 °C. 
Čvrsti oblik prema zahtjevu 1, naznačen time što pokazuje gubitak težine od oko 0.16% ukupne mase uzorka nakon grijanja od oko 25 do oko 120 °C.
In one embodiment, wherein at least about 20% to about 50% of the N-linked oligosaccharides in the glycoengineered Fc region are bisected, nonfucosylated. 
Protutijelo u skladu sa zahtjevom 7, naznačeno time, da su najmanje 20% do 50% N-vezanih oligosaharida u Fc regiji prepolovljeni, nefukozilirani.
The solution was filled into 10 ml vials at 1 ml/vial and maintained at −20° C. until lyophilization process. 
Otopina je napunjena u 10 ml ampule u količini od 1 ml/ampuli i održavana na -20*C do procesa liofilizacije.
The compound of any one of claims 1-4 wherein the hematological cancer is leukemia, preferably selected from acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, myeloproliferative disorder/neoplasm and myelodysplastic syndrome, and further preferably wherein the leukemia is human acute myeloid leukemia. 
Farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 19, pri čemu je malignitet leukemija. Farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 20, pri čemu je leukemija odabrana između akutne limfocitne leukemije, kronične limfocitne leukemije, kronične mijeloične leukemije, mijeloproliferativnog poremećaja/neoplazme 1 mijelodisplastičnog sindroma.
Drying under vacuum at 33°C overnight gave the title compound (m=4.786g) in a 96% yield. 
Sušenjem pod vakuumom dobije se spoj iz naslova (m = 4,786 g) s prinosom od 96 %.
A nucleic acid molecule encoding the antibody according to any of claims 1 to 11, or an antigen-binding fragment thereof according to claim 12 or 13. 
Molekula nukleinske kiseline, naznačena time što kodira protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 11, ili njegov antigenski vežući fragment u skladu s patentnim zahtjevom 12 ili 13.
An immunogenic composition according to claim 1 or claim 2 wherein at least serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F are present as conjugated saccharides. 
saharid iz kapsule serotipa 18C, konjugiran s tetanusnim toksoidom (TT); saharidi iz kapsule serotipova 1, 4, 5, 6B, 7F, 9V, 14 i 23F, konjugirani s proteinom D iz bakterije Haemophilus influenzae.
the hard vegetable butter in an amount of 15 to 35 wt.%, and 
tvrdi biljni maslac u količini od 15 do 35 mas. %, i
Arrangement for containment according to claim 1 or 2, wherein the secondary barrier (3) is sprayed onto the interior surface of the hull compartment. 
Naprava za zadržavanje u skladu sa zahtjevom 1 ili 2, naznačena time što se je sekundarna barijera (3) raspršena na unutarnju površinu odjeljka trupa.
Tumble Rate/ (10 Coin 
(10) Identifikator dokumenta:
• Check phase EV3) Single choice: if (yes) it accesses E4, if (no) it accesses E3; 
Kontrolna faza EV3) pojedinačan izbor: ako (da) pristupa E4, ako (ne) pristupa E3;
a fuel gas supply line configured to extract LNG from the LNG tank and supply the extracted LNG as fuel gas to the high-pressure gas injection engine; 
drugu crpku (4) konfiguriranu da dodatno stlačuje LNG na visoki pritisak i da dobavlja dodatno komprimirani LNG prema visokotlačnom plinskom injekcijskom motoru;
The transdermal delivery device of claim 4, wherein the microspheres consist essentially of the opioid antagonist and a polymer selected from the group consisting of polyesters, polyethers, poly(orthoesters), polysaccharides, cyclodextrins, chitosans, poly (∑- caprolactones), polyanhydrides, albumin, blends and copolymers thereof. 
Sredstvo za transdermalno davanje prema zahtjevu 1, naznačeno time da se mikrosfere u osnovi sastoje od opioidnog antagonista i polimera odabranog iz skupine koja se sastoji od poliestera, polietera, poli(ortoestera), polisaharida, ciklodekstrina, citosana, poli (E-kaprolaktona), polianhidrida, albumina, njihovih mješavina i kopolimera.
The method of claim 3, wherein the hydrogen donor is methanol, ethanol, propan-1-ol, propan-2-ol, butan-1-ol, butan-2-ol, cyclopentanol, cyclohexanol, benzylalcohol, a menthol, formic acid, lactic acid, ascorbic acid, mandelic acid, ammonium formate, potassium formate, cyclohexadiene, cyclohexene, 1-methylcyclohexene, tetralin, dihydrofuran, a terpene, diazene, hydrazine, hydroxylamine, or NaH2PO2, or a mixture thereof. The method of claim 3, wherein the hydrogen donor is a C1-14 carboxylic acid. The method of claim 5, wherein the hydrogen donor is formic acid. 
Postupak u skladu s patentnim zahtjevom 3, naznačen time što je donor vodika metanol, etanol, propan-1-ol, propan-2-ol, butan-1-ol, butan-2-ol, ciklopentanol, cikloheksanol, benzilalkohol, mentol, mravlja kiselina, mliječna kiselina, askorbinska kiselina, bademova Kiselina, amonijev formijat, kalijev formijat, cikloheksadien, cikloheksen, 1-metilcikloheksen, tetralin, dihidrofuran, terpen, diazen, hidrazin, hidroksilamin ili NaH2PO2, ili njihova smjesa; ili gdje je donor vodika mravlja kiselina, amonijev formijat, kalijev formijat, cikloheksen, 1-metilcikloheksen, NaH2P02, ili njihova smjesa; ili gdje je donor vodika C1-14 karboksilna kiselina.
In one aspect of the Amino Acid unit, the Amino Acid unit is valine-citrulline (vc or Val-Cit). 
Formula Hla; amino kiselinska jedinica je Valin-Citrulin (Val-Ci1ft); te jedinica za razmak ima strukturu formule Xa:
is C6-10aryl, such as phenyl, and “*” means a chiral center with absolute stereochemistry (R) or (S), with an acidic reagent to provide the compound of formula (I). 
"*" znači kiralni centar s apsolutnom stereokemijom (R) ili (S); te od rastavaranja rezultirajuće dijastereomerne smjese putem kristalizacije, za dobivanje spoja formule (II).
Such diseases include, but are not limited to Parkinson's disease, familial Parkinson's disease, Lewy body disease, the Lewy body variant of Alzheimer's disease, dementia with Lewy bodies, multiple system atrophy, and the Parkinsonism-dementia complex of Guam. 
Spoj za uporabu prema zahtjevu 4 naznačen time da je sinukleinopatija odabrana iz skupine koju čine Parkinsonova bolest, nasljedna Parkinsonova bolest, bolest Lewyjevih tjelešaca, varijanta Alzheimerove bolesti s Lewyjevim tjelešcima, demencija s Lewyjevim tjelešcima, multipla sistemska atrofija, te kompleks Guam demencije s parkinsonizmom.
the treatment of latent tuberculosis; 
(b) liječenju latentne tuberkuloze;
a QAM demapper configured to demap the deinterleaved constellation values into cell words and to multiplex the demapped cell words into the PLP data; 
dio za demapiranje QAM-a (r713-L1) podešen za demapiranje raspletenih konstelacijskih vrijednosti u stanične riječi i za umnožavanje demapiranih staničnih riječi u PLP podatke;
The modified sulfamidase or the sulfamidase composition according to embodiment 33, for use in treatment of a mammal afflicted with a lysosomal storage disease, in particular mucopolysaccharidosis IIIA (MPS IIIA). 
Modificirana sulfamidaza ili supstanca sulfamidaze sukladno patentnom zahtjevu 15, radi liječenja sisavaca s bolesti lizozomnog skladištenja, specifično mukopolisaharidoza INA (MPS IIIA).
A checking centre (30) specially adapted for authenticating an item (43) by the method of any of claims 21 to 24. A system for marking manufactured items comprising: 
Kontrolni centar (30), naznačen time, da je specijalno prilagođen za ustanovljavanje autentičnosti artikla(43) po metodi bilo kojeg od patentnih zahtjeva 21 do 24.
Inhibitory effects of the compounds of formula (I) against angiotensin II induced pressor response in dogs 
Uporaba, naznačena time, da se koristi spoj prikazan formulom (I) N.
The message controller as claimed in claim 1, wherein the message controller is adapted to extract the MSISDN or equivalent in the original routing query and to determine what further information could be obtained in addition to what was requested in the original routing query. 
Kontroler poruka prema zahtjevu 1, pri čemu je kontroler poruka prilagođen da ekstrahira MSISDN ili njegov ekvivalent iz originalnog upita za dostavljanje informacija o rutiranju i odredi koje se dodatne informacije mogu dobiti u odnosu na one koje su zahtijevane originalnim upitom za dostavljanje informacija o rutiranju.
Example 11: Inhibition of VEGF Secretion in Tumor Cells 
(V) inhibicija izlučivanja VEGF od strane stanica koje eksprimiraju ErbB3;
a first portion of a second color, being visible to the at least one image sensor, and 
Sustav prema zahtjevu 26, naznačen time da kamera sadrži barem jedan senzor za sliku.
A compound of the formula (I) in which 
PATENTNI ZAHTJEVI 1. Spoj formule (I)
Intermediate (29) is then converted to intermediate (20) by reaction with a reagent suitable for introducing a benzyloxycarbonyl (“Z”) group onto the nitrogen atom of the dihydroisoindole ring. 
PG-O o PG (3a) s Wittigovim reagensom ili drugim reagensom prikladnim za pretvaranje skupine -C(=0)-CH3 u skupinu - C(=CH>)-CH:.
A compound according to claim 1, or a stereoisomer or a pharmaceutically acceptable salt thereof, for use in the treatment of a disorder selected from the group consisting of narcolepsy or sleep/wake disorders, feeding behavior disorders, eating disorders, obesity, cognition disorder, arousal disorder, memory disorder, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders, epilepsy, gastrointestinal disorders, respiratory disorders, inflammation, and myocardial infarction. 
Spoj prema patentnom zahtjevu 1, ili njegov stereoizomer ili njegova farmaceutski prihvatljiva sol, naznačen time, da je za uporabu u liječenju poremećaja odabranog iz skupine koja sadrži narkolepsiju ili poremećaje spavanja/budnosti, poremećaje ponašanja pri hranjenju, poremećaje hranjenja, pretilost, kognitivni poremećaj, poremećaj pobuđenosti, poremećaj pamćenja, poremećaje raspoloženja, promjenu raspoloženja i pažnje, poremećaj hiperaktivnosti i deficita pažnje, Alzheimerovu bolest/demenciju, shizofreniju, bol, stres, migrenu, kinetozu, depresiju, psihijatrijske poremećaje, epilepsiju, gastromtestinalne poremećaje, respiratorne poremećaje, upalu, i infarkt miokarda.
As is shown in FIG. 5 the connection unit may be adjusted so that two and more rock bolts 7 ′, 7 ″ may be joined together in order to form a long bolt. 
Kako je prikazano na Slici 5 vezna jedinica može se prilagoditi tako, da se dva ili više sidara u stijeni 7', 7" mogu spojiti zajedno da bi se oblikovalo dugo sidro.
at least one XRPD peak, in terms of 2-theta, selected from about 18.4°, about 18.9°, about 21.8°, about 23.9°, about 29.2°, and about 38.7°; or 
Čvrsti oblik spoja prema patentnom zahtjevu 15 koji ima najmanje jedan pik XRPD, u uvjetima na 2-teta +/- 0.2 °, izabrana od 18,4°, 18,9°, 21,8°, 23,9°, 29,2° i 38,7°.
An expression vector encoding the antibody of claim 1, comprising a nucleic acid sequence depicted in SEQ ID NO 89, or its conservative sequence variant, or a nucleotide sequence depicted in SEQ ID NO 90, or its conservative sequence variant. 
Ekspresijski vektor prema zahtjevu 7, koji sadrži sekvencu nukleotida izabranu iz skupine koja se sastoji od SEQ ID NO:s 64 do 68 1 njihovih konzervativnih varijanta sekvenci. Ekspresijski vektor prema zahtjevu 7, koji sadrži sekvencu nukleotida prikazanu u SEQ ID NO 89 i njenu konzervativnu varijantu sekvence.
A therapeutic nanoparticle for use as a medicament, as claimed in claim 2, wherein the nanoparticle comprises about 0.2 to about 25 weight percent of the therapeutic agent and about 50 to about 99.75 weight percent of the polymer and wherein the nanoparticle comprises about 10 to about 30 weight percent poly(ethylene)glycol. 
Terapijska nanočestica u skladu s patentnim zahtjevom 2, naznačena time što sadrži otprilike 0,2 do otprilike 25 težinskih postotaka terapijskog sredstva i otprilike 50 do otprilike 99,75 težinskih postotaka polimera, te što nanočestica sadrži otprilike 10 do otprilike 30 težinskih postotaka poli(etilen)glikola.
contacting a compound which stimulates functionality of the receptor in step (b) in vitro with a vertebrate enteroendocrine cell or with a cell capable of secreting GIP; and 
(b) određivanje sposobnosti test spoja za stimulaciju djelotvornosti receptora; pri čemu sposobnost test spoja za stimulaciju djelotvornosti receptora pokazuje da li je test spoj postao GIP sekretogog.
The ketone synthesised as described in patent application WO 00/06579 is treated with p-toluenesulphonic acid and piperazine, so as to yield the corresponding enamine. 
Keton sintetiziran kao što je opisano u međunarodnoj patentnoj prijavi objavljenoj kao WO 00/06579 obrađuje se s p-toluensulfonskom kiselinom i piperazinom, kako bi se dobilo odgovarajući enamin.